Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Dactinomycin.
Afatinib
The serum concentration of Afatinib can be increased when it is combined with Dactinomycin.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Dactinomycin.
Advertisement
Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Dactinomycin.
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Anthrax immune globulin human.
Apalutamide
The serum concentration of Dactinomycin can be decreased when it is combined with Apalutamide.
Advertisement
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Dactinomycin.
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Bacillus calmette-guerin substrain connaught live antigen.
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Bacillus calmette-guerin substrain tice live antigen.
Advertisement
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Dactinomycin.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Dactinomycin.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Dactinomycin.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Dactinomycin.
Brentuximab Vedotin
The serum concentration of Brentuximab vedotin can be increased when it is combined with Dactinomycin.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Dactinomycin.
Clozapine
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Clozapine.
Colchicine
The serum concentration of Colchicine can be increased when it is combined with Dactinomycin.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Dactinomycin.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Dactinomycin.
Dabigatran Etexilate
The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Dactinomycin.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Dactinomycin.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Dactinomycin.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Dactinomycin.
Digoxin
Digoxin may decrease the cardiotoxic activities of Dactinomycin.
Dipyrone
The risk or severity of myelosuppression can be increased when Metamizole is combined with Dactinomycin.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Dactinomycin.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Dactinomycin.
Doxorubicin
The serum concentration of Doxorubicin can be increased when it is combined with Dactinomycin.
Doxorubicin Hydrochloride
The serum concentration of Doxorubicin can be increased when it is combined with Dactinomycin.
Edoxaban
The serum concentration of Edoxaban can be increased when it is combined with Dactinomycin.
Eltrombopag
The serum concentration of Dactinomycin can be increased when it is combined with Eltrombopag.
Everolimus
The serum concentration of Everolimus can be increased when it is combined with Dactinomycin.
Fingolimod
Dactinomycin may increase the immunosuppressive activities of Fingolimod.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Hepatitis B Vaccine (Recombinant).
Isavuconazole
The serum concentration of Dactinomycin can be increased when it is combined with Isavuconazole.
Ledipasvir
The serum concentration of Ledipasvir can be increased when it is combined with Dactinomycin.
Leflunomide
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Leflunomide.
Lumacaftor
The serum concentration of Dactinomycin can be decreased when it is combined with Lumacaftor.
Naloxegol
The serum concentration of Naloxegol can be increased when it is combined with Dactinomycin.
Natalizumab
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Natalizumab.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Dactinomycin.
Ouabain
Ouabain may decrease the cardiotoxic activities of Dactinomycin.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Dactinomycin.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Dactinomycin.
Pazopanib
The serum concentration of Pazopanib can be increased when it is combined with Dactinomycin.
Picosulfuric Acid
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Dactinomycin.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Dactinomycin.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Dactinomycin.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Dactinomycin.
Ranolazine
The serum concentration of Ranolazine can be increased when it is combined with Dactinomycin.
Rifaximin
The serum concentration of Rifaximin can be increased when it is combined with Dactinomycin.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Dactinomycin.
Rolapitant
The serum concentration of Dactinomycin can be increased when it is combined with Rolapitant.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Rubella virus vaccine.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Salmonella typhi ty21a live antigen.
Silodosin
The serum concentration of Silodosin can be increased when it is combined with Dactinomycin.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dactinomycin.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Dactinomycin.
Teriflunomide
The serum concentration of Dactinomycin can be increased when it is combined with Teriflunomide.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Tofacitinib
Dactinomycin may increase the immunosuppressive activities of Tofacitinib.
Topotecan
The serum concentration of Topotecan can be increased when it is combined with Dactinomycin.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Dactinomycin.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Varicella Zoster Vaccine (Live/Attenuated).
Vemurafenib
The serum concentration of Dactinomycin can be increased when it is combined with Vemurafenib.
Vincristine
The excretion of Vincristine can be decreased when combined with Dactinomycin.
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Yellow Fever Vaccine.
